The role of p53 immunohistochemical marker in development of superficial urothelial bladder carcinoma

Purpose. Determination the role of the p53 expression as a prognostic factor in the development of superficial urothelial bladder carcinoma.

Materials and methods. Medical histories of 72 patients (11 women and 61 men) with diagnosed primary superficial urothelial carcinoma of the bladder I and II grade were retrospectively analyzed. All patients were undergone a repeated transurethral resection was performed in 6 weeks after the first operation. In the case of the absence of residual tumor, cystoscopy was performed every 3 months during the first year then every 3–6 months during next 5 years. The average time of follow-up was 43.2 months. According to the standard protocol an immunohistochemical study with detection of p53 was carried out on 72 sections of formalin-fixed and paraffin-embedded tumor fragments. p53 expression was also determined in 10 histologically unchanged fragments of the bladder mucosa.

Results. Depending on the percent of nuclei with p53 expression, two groups were identified. The first group included 40 tumor samples (55.5 %) with p53 expression less than 20 % and 17 tumor samples (23.6 %) without p53 expression. The second group included 15 tumor samples (20.9 %) with p53 expression more than 20 % (4 patients – 20–40 %, 8 patients – 40–60 %, 3 patients – 60–80 %). р53 expression was not determined in the all 10 samples of normal bladder tissue. During follow-up period 1 of 57 patients of the first group has a disease progression comparing with 13 of 15 patients in the second group. Patients of the both group were similar in respect with clinical characteristics. The mean time to disease progression was 17.3 months.

Conclusion. Results of the current study shows that p53 immunohistochemical marker is a prognostic factor in the development of superficial urothelial bladder carcinoma.

1. Chaux A., Karram S., Miller J.S. et al. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/ International Society of Urological Pathology classification cohort from a single academic center. Hum Pathol 2012;43(1):115–20. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21820145.

2. Cheng L., MacLennan G.T., Lopez-Beltran A. Histologic grading of urothelial carcinoma: a reappraisal. Hum Pathol 2012;43(12):2097–108. Available at: http://www.ncbi.nlm.nih.gov/pubmed/?term=Histologic+grading+of+urothelial+carcinoma%3A+a+reappraisal.

3. Cheng L., Zhang S., MacLennan G.T.et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011;42(4):455–81. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/?term=Bladder+cancer%3A+translating+molecular+genetic+insights+into+clinical+practice.

4. Goebell P.J., Groshen S.G., Schmitz-Dräger B.J. p53 immunohistochemistry in bladder cancer – a new approach to an old question. Urol Oncol 2010;28(4):377–88. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20610276.

5. Matsushita K., Cha E.K., Matsumoto K. et al. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol 2011;18(9):616–29. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21771101.

6. Pan C.C., Chang Y.H., Chen K.K. et al. Prognostic significance of the 2004 WHO/ ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 2010;133(5):788–95. Available at: http://www.ncbi.nlm.nih.gov/pubmed/?term=Prognostic+significance+of+the+2004+WHO%2FISUP+classification+for+prediction+of+recurrence.

7. Resnick M.J., Basset J.C., Clark P.E. Management of superficial and muscleinvasive urothelial cancers of the bladder. Curr Opin Oncol 2013;25(3):281–8.

8. Gontero P., Casetta G., Zitella A. et al. Evaluation of p53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumor recurrence in superficial transitional cell carcinoma of bladder. Eur Urol 2000;38(3):287–96.

9. Jiang D.K., Ren W.N. Yao L. et al. Metaanalysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 2010;76(3):765.e1–7.

10. Oh J.J., Si S.H., Choi D.K. et al. A sixweek course of bacillus Calmette-Guerin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong positive expression of p53. Oncology 2010;79(5–6):440–6.